ag真人平台官方

<tr id='699zs'><strong id='LCmJ1'></strong><small id='s8z8f'></small><button id='uA3dL'></button><li id='pberx'><noscript id='tMSIk'><big id='XemEY'></big><dt id='91C1G'></dt></noscript></li></tr><ol id='Ye3RV'><option id='8dRbn'><table id='ykNe3'><blockquote id='45Rb9'><tbody id='9UNzc'></tbody></blockquote></table></option></ol><u id='oU6jg'></u><kbd id='E9bGW'><kbd id='kixFA'></kbd></kbd>

<code id='LLc3p'><strong id='mceqH'></strong></code>

<fieldset id='SkCVc'></fieldset>

<span id='7VGJw'></span>

<ins id='NMZpY'></ins>

<acronym id='pWrlO'><em id='tIZhw'></em><td id='92mw9'><div id='wTDzz'></div></td></acronym><address id='Gy3Gy'><big id='L8CzW'><big id='F03oA'></big><legend id='5vWhU'></legend></big></address>

<i id='cN8pp'><div id='PHIt2'><ins id='az64R'></ins></div></i>

<i id='AZ1SV'></i>

Other Affiliated Sites

Create Value for Investors Through

Safe and Stable Operations

Disclosures

A-Share Information

H-Share Information

FIRST PATIENT DOSED IN THE PHASE 3 CLINICAL TRIAL OF OREGOVOMAB

"INHIXA" OBTAINS APPROVAL FROM SFDA

Monthly Return of Equity Issuer on Movements in Securities for the month ended 3...

Notification Letter and Request Form to Non-Registered Shareholder

2020 Interim Report

第一页上一页 15 16 17 18 19 下一页最后一页